Bayer AG has entered into a takeover agreement with Cara Care

Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.

Cara Care is a digital digestive health solution from Germany that combines both mental and nutritional therapy options. Its MDR Class I-approved treatment for irritable bowel syndrome (IBS) is fully reimbursed by all German statutory health insurance (SHI) and DiGA-certified providers. DiGA refers to digital health applications that are approved for use in Germany and are eligible for reimbursement under the country’s SHI system. The company is a pioneer in the field and is driving growth in an underserved sector. Cara Care has built a product pipeline that addresses not only IBS but also heartburn, dyspepsia and inflammatory bowel disease (IBD).

Bayer AG is a global enterprise with core competencies in the life sciences fields of healthcare and agriculture. Founded in 1863 and headquartered in Leverkusen, Germany, Bayer is known for its innovation-driven approach to improving quality of life. The company operates across three main divisions: pharmaceuticals, consumer health and crop science, delivering products and solutions that address some of the world’s most pressing challenges, particularly in health and food security.

Oaklins’ team in Germany provided comprehensive advisory services to the insolvency administrator and Cara Care in this transaction.